Building on the initial efforts of the IMbrave 150 trial (NCT03434379), the combinational regimen of atezolizumab (an anti-PD-L1 antibody) plus bevacizumab [a monoclonal antibody against vascular endothelial growth factor (VEGF)] has been approved as the first-line treatment in HCC (46). This evidence concerns the gene VEGFA and hepatocellular carcinoma.